At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
AZD2171drug
Likely dose
AZD2171 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate
In Brief
A Phase 2 clinical trial evaluating AZD2171 for Gastrointestinal Stromal Tumors and Soft Tissue Sarcomas. Completed, enrolled 35 participants across 2 sites.
Detailed Summary
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedOct 2006
Primary CompletionJun 2008
Study CompletionDec 2009
TodayJul 2026
First PostedOct 6, 2006
Enrollment StartSep 1, 2006
Primary CompletionJun 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.7 years ago
Interventions
AZD2171drug
45 mg oral tablet once daily dose